Aliskiren, the First Renin Inhibitor for Treating Hypertension: Reactive Renin Secretion May Limit Its Effectiveness
| Autor: | Jean E. Sealey, John H. Laragh |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Angiotensin-Converting Enzyme Inhibitors Blood Pressure Pharmacology Renin inhibitor Plasma renin activity Renovascular hypertension chemistry.chemical_compound Fumarates Internal medicine Renin Renin–angiotensin system Internal Medicine medicine Humans Antihypertensive Agents Clinical Trials as Topic business.industry Aliskiren medicine.disease Amides Angiotensin II Blood pressure Endocrinology chemistry Hypertension ACE inhibitor Drug Therapy Combination Female business medicine.drug |
| Zdroj: | American Journal of Hypertension. 20:587-597 |
| ISSN: | 0895-7061 |
| Popis: | A review of six clinical trials of aliskiren involving >5,000 patients with mild to moderate hypertension indicated that this first of a new class of orally active antihypertensive drugs is no more effective than angiotensin-converting enzyme inhibitors (CEIs), angiotensin receptor blockers (ARBs), or diuretics for lowering blood pressure. The starting dose is 150 mg; 300 mg is usually more effective, but 600 mg is no better than 300 mg. Aliskiren in combination with a diuretic appeared to lower blood pressure more than an aliskiren-ARB combination, but still failed to control blood pressure ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|